Works by Yada, Masayoshi

Results: 25

Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.

Published in:

Cancer Science, 2006, v. 97, n. 8, p. 729, doi. 10.1111/j.1349-7006.2006.00239.x

By:

Fujii, Yo;
Yada, Masayoshi;
Nishiyama, Masaaki;
Kamura, Takumi;
Takahashi, Hidehisa;
Tsunematsu, Ryosuke;
Susaki, Etsuo;
Nakagawa, Tadashi;
Matsumoto, Akinobu;
Nakayama, Keiichi I.

Publication type:

Article

Risk factors for loss to follow‐up after the start of direct‐acting antiviral treatment for hepatitis C virus infection.

Published in:

JGH Open, 2023, v. 7, n. 2, p. 98, doi. 10.1002/jgh3.12855

By:

Kuwano, Akifumi;
Yada, Masayoshi;
Kurosaka, Kazuki;
Tanaka, Kosuke;
Masumoto, Akihide;
Motomura, Kenta

Publication type:

Article

Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.

Published in:

Journal of Viral Hepatitis, 2022, v. 29, n. 7, p. 543, doi. 10.1111/jvh.13681

By:

Kuwano, Akifumi;
Yada, Masayoshi;
Nagasawa, Shigehiro;
Tanaka, Kosuke;
Morita, Yusuke;
Masumoto, Akihide;
Motomura, Kenta

Publication type:

Article

Serum α‐fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct‐acting antiviral treatment.

Published in:

Journal of Viral Hepatitis, 2022, v. 29, n. 1, p. 35, doi. 10.1111/jvh.13625

By:

Kuwano, Akifumi;
Yada, Masayoshi;
Nagasawa, Shigehiro;
Tanaka, Kosuke;
Morita, Yusuke;
Masumoto, Akihide;
Motomura, Kenta

Publication type:

Article

Similar Efficacy Between Atezolizumab Plus Bevacizumab Versus Hepatic Arterial Infusion Chemotherapy For Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Cohort Study.

Published in:

In Vivo, 2024, v. 38, n. 4, p. 1854, doi. 10.21873/invivo.13639

By:

AKIFUMI KUWANO;
MASAYOSHI YADA;
KOSUKE TANAKA;
YUTA KOGA;
SHIGEHIRO NAGASAWA;
AKIHIDE MASUMOTO;
KENTA MOTOMURA

Publication type:

Article

Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.

Published in:

Journal of Medical Virology, 2013, v. 85, n. 2, p. 250, doi. 10.1002/jmv.23464

By:

Kohjima, Motoyuki;
Enjoji, Munechika;
Yoshimoto, Tsuyoshi;
Yada, Ryoko;
Fujino, Tatsuya;
Aoyagi, Yoko;
Fukushima, Nobuyoshi;
Fukuizumi, Kunitaka;
Harada, Naohiko;
Yada, Masayoshi;
Kato, Masaki;
Kotoh, Kazuhiro;
Nakashima, Manabu;
Sakamoto, Naoya;
Tanaka, Yasuhito;
Nakamuta, Makoto

Publication type:

Article

Prognostic Significance of Lymphocyte-to-Monocyte Ratio in Patients With Unresectable Biliary Tract Cancer Undergoing Systemic Chemotherapy.

Published in:

Cancer Diagnosis & Prognosis, 2025, v. 5, n. 1, p. 132, doi. 10.21873/cdp.10422

By:

HIDEO SUZUKI;
AKIFUMI KUWANO;
JUNRO TAKAHIRA;
KOSUKE TANAKA;
MASAYOSHI YADA;
KENTA MOTOMURA

Publication type:

Article

Systemic Chemotherapy for Advanced Hepatocellular Carcinoma in Patients With Child-Pugh class B.

Published in:

Cancer Diagnosis & Prognosis, 2024, v. 4, n. 2, p. 111, doi. 10.21873/cdp.10295

By:

AKIFUMI KUWANO;
MASAYOSHI YADA;
KOSUKE TANAKA;
YUTA KOGA;
SHIGEHIRO NAGASAWA;
AKIHIDE MASUMOTO;
KENTA MOTOMURA

Publication type:

Article

Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Published in:

Cancer Diagnosis & Prognosis, 2024, v. 4, n. 1, p. 34, doi. 10.21873/cdp.10282

By:

AKIFUMI KUWANO;
MASAYOSHI YADA;
KOSUKE TANAKA;
YUTA KOGA;
SHIGEHIRO NAGASAWA;
AKIHIDE MASUMOTO;
KENTA MOTOMURA

Publication type:

Article

Combined Ultrasound and Computed Tomography Guidance in Radiofrequency Ablation for Hepatocellular Carcinoma Reduces Local Recurrence Rate.

Published in:

Cancer Diagnosis & Prognosis, 2023, v. 3, n. 6, p. 660, doi. 10.21873/cdp.10269

By:

SHIGEHIRO NAGASAWA;
AKIFUMI KUWANO;
KOSUKE TANAKA;
MASAYOSHI YADA;
AKIHIDE MASUMOTO;
KENTA MOTOMURA

Publication type:

Article

An Imaging Feature Predicts Efficacy of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Published in:

Cancer Diagnosis & Prognosis, 2023, v. 3, n. 4, p. 468, doi. 10.21873/cdp.10241

By:

AKIFUMI KUWANO;
MASAYOSHI YADA;
YOSHIKO MIYAZAKI;
KOSUKE TANAKA;
YUTA KOGA;
YOSHIHIRO OHISHI;
AKIHIDE MASUMOTO;
KENTA MOTOMURA

Publication type:

Article

Tumor‐infiltrating CD8<sup>+</sup> T‐cell numbers and serum C‐reactive protein levels as a prognostic biomarker in hepatocellular carcinoma patients receiving atezolizumab plus bevacizumab.

Published in:

Hepatology Research, 2025, v. 55, n. 4, p. 600, doi. 10.1111/hepr.14157

By:

Kuwano, Akifumi;
Yada, Masayoshi;
Tanaka, Kosuke;
Takahira, Junro;
Suzuki, Hideo;
Ohishi, Yoshihiro;
Motomura, Kenta

Publication type:

Article

Expression profile of lipid metabolism-associated genes in hepatitis C virus-infected human liver.

Published in:

Hepatology Research, 2010, v. 40, n. 9, p. 923, doi. 10.1111/j.1872-034X.2010.00700.x

By:

Fujino, Tatsuya;
Nakamuta, Makoto;
Yada, Ryoko;
Aoyagi, Yoko;
Yasutake, Kenichiro;
Kohjima, Motoyuki;
Fukuizumi, Kunitaka;
Yoshimoto, Tsuyoshi;
Harada, Naohiko;
Yada, Masayoshi;
Kato, Masaki;
Kotoh, Kazuhiro;
Taketomi, Akinobu;
Maehara, Yoshihiko;
Nakashima, Manabu;
Enjoji, Munechika

Publication type:

Article

Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/β-catenin signal activation.

Published in:

Oncology Letters, 2022, v. 24, n. 1, p. N.PAG, doi. 10.3892/ol.2022.13337

By:

Kuwano, Akifumi;
Yada, Masayoshi;
Narutomi, Fumiya;
Nagasawa, Shigehiro;
Tanaka, Kosuke;
Kurosaka, Kazuki;
Ohishi, Yoshihiro;
Masumoto, Akihide;
Motomura, Kenta

Publication type:

Article

Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI.

Published in:

Molecular & Clinical Oncology, 2022, v. 16, n. 2, p. 1, doi. 10.3892/mco.2021.2486

By:

AKIFUMI KUWANO;
KOSUKE TANAKA;
MASAYOSHI YADA;
SHIGEHIRO NAGASAWA;
YUSUKE MORITA;
AKIHIDE MASUMOTO;
KENTA MOTOMURA

Publication type:

Article

Diagnostic features of autoimmune hepatitis in SARS-CoV-2-vaccinated vs. unvaccinated individuals.

Published in:

Experimental & Therapeutic Medicine, 2024, v. 28, n. 3, p. 1, doi. 10.3892/etm.2024.12626

By:

AKIFUMI KUWANO;
SHIGEHIRO NAGASAWA;
YUTA KOGA;
KOSUKE TANAKA;
MASAYOSHI YADA;
AKIHIDE MASUMOTO;
KENTA MOTOMURA

Publication type:

Article

FIB‑4 index and serum α‑fetoprotein are useful predictors of hepatocellular carcinoma occurrence in hepatitis B patients with nucleos(t)ide analogs therapy.

Published in:

Experimental & Therapeutic Medicine, 2023, v. 26, n. 3, p. N.PAG, doi. 10.3892/etm.2023.12140

By:

Kuwano, Akifumi;
Miyazaki, Masayuki;
Yada, Masayoshi;
Tanaka, Kosuke;
Koga, Yuta;
Masumoto, Akihide;
Motomura, Kenta

Publication type:

Article

Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice.

Published in:

Cancers, 2023, v. 15, n. 17, p. 4345, doi. 10.3390/cancers15174345

By:

Motomura, Kenta;
Kuwano, Akifumi;
Tanaka, Kosuke;
Koga, Yuta;
Masumoto, Akihide;
Yada, Masayoshi

Publication type:

Article

Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.

Published in:

EMBO Journal, 2004, v. 23, n. 10, p. 2116, doi. 10.1038/sj.emboj.7600217

By:

Yada, Masayoshi;
Hatakeyama, Shigetsugu;
Kamura, Takumi;
Nishiyama, Masaaki;
Tsunematsu, Ryosuke;
Imaki, Hiroyuki;
Ishida, Noriko;
Okumura, Fumihiko;
Nakayama, Keiko;
Nakayama, Keiichi I.

Publication type:

Article

Molecular clearance of ataxin-3 is regulated by a mammalian E4.

Published in:

EMBO Journal, 2004, v. 23, n. 3, p. 659, doi. 10.1038/sj.emboj.7600081

By:

Matsumoto, Masaki;
Yada, Masayoshi;
Hatakeyama, Shigetsugu;
Ishimoto, Hiroshi;
Tanimura, Teiichi;
Tsuji, Shoji;
Kakizuka, Akira;
Kitagawa, Masatoshi;
Nakayama, Keiichi I.

Publication type:

Article

Interaction of U-box-type ubiquitin-protein ligases (E3s) with molecular chaperones.

Published in:

Genes to Cells, 2004, v. 9, n. 6, p. 533, doi. 10.1111/j.1356-9597.2004.00742.x

By:

Hatakeyama, Shigetsugu;
Matsumoto, Masaki;
Yada, Masayoshi;
Keiichi I. Nakayama

Publication type:

Article

Dynamics of the neutrophil‑to‑lymphocyte ratio during lenvatinib treatment for unresectable hepatocellular carcinoma.

Published in:

Oncology Letters, 2024, v. 28, n. 1, p. N.PAG, doi. 10.3892/ol.2024.14442

By:

Kuwano, Akifumi;
Yada, Masayoshi;
Koga, Yuta;
Tanaka, Kosuke;
Ohishi, Yoshihiro;
Masumoto, Akihide;
Motomura, Kenta

Publication type:

Article

Tumor‑infiltrating CD8<sup>+</sup> T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma.

Published in:

Oncology Letters, 2023, v. 25, n. 6, p. N.PAG, doi. 10.3892/ol.2023.13845

By:

Kuwano, Akifumi;
Yada, Masayoshi;
Miyazaki, Yoshiko;
Tanaka, Kosuke;
Kurosaka, Kazuki;
Ohishi, Yoshihiro;
Masumoto, Akihide;
Motomura, Kenta

Publication type:

Article

Mammalian E4 Is Required for Cardiac Development and Maintenance of the Nervous System.

Published in:

Molecular & Cellular Biology, 2005, v. 25, n. 24, p. 10953, doi. 10.1128/MCB.25.24.10953-10964.2005

By:

Kaneko-Oshikawa, Chie;
Nakagawa, Tadashi;
Yamada, Mitsunori;
Yoshikawa, Hiroo;
Matsumoto, Masaki;
Yada, Masayoshi;
Hatakeyama, Shigetsugu;
Nakayama, Keiko;
Nakayama, Keiichi I.

Publication type:

Article

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.

Published in:

Internal Medicine, 2022, v. 61, n. 21, p. 3157, doi. 10.2169/internalmedicine.9237-21

By:

Rie Sugimoto;
Kenta Motomura;
Aritsune Ooho;
Yoshifusa Aratake;
Akihiro Ueda;
Takeshi Senju;
Yuki Tanaka;
Masayoshi Yada;
Kohsuke Tanaka;
Akifumi Kuwano;
Yuusuke Morita;
Shigehiro Nagasawa;
Mari Ooe;
Taiji Mutsuki;
Tsuyoshi Yoshimoto;
Naoki Yamashita;
Mai Nakashima;
Tomonobu Hioki;
Toshimasa Koyanagi;
Nobito Higuchi

Publication type:

Article